Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
This is a multi-center, open label, repeat dose, Phase 1 study consisting of a Dose Escalation Phase and a Dose Expansion Phase to evaluate safety, pharmacokinetics, and clinical activity.
Colorectal Adenocarcinoma|Gastric Adenocarcinoma|Pancreatic Adenocarcinoma|Bile Duct Carcinoma|Hepatocellular Carcinoma|Esophageal Carcinoma|Gastrointestinal Cancer
DRUG: CGX1321
Number of participants with adverse events and/or abnormal laboratory values that are related to treatment, 21 months
CGX1321 maximum or peak concentration, 30 days|CGX1321 minimum or trough concentration, 30 days|CGX1321 time to maximum concentration, 30 days|CGX1321 half life, 30 days
The purpose of the Dose Escalation Phase is to examine the safety and determine the maximum tolerated dose of CGX1321 when administered to subjects with advanced GI tumors that have relapsed or are refractory to or not considered medically suitable to receive standard of care treatment.

Once the dose is identified in the Dose Escalation Phase, the Dose Expansion Phase will start. The purpose of the Dose Expansion Phase is to continue to examine the safety and confirm the final Phase 2 dose of CGX1321 when administered to subjects with advanced GI tumors who meet the entry criteria.